Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.ACGN · Entity 110652 | CHIEF MEDICAL OFFICER | January 20, 2023 | February 02, 2023 |
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Medical Officer | October 15, 2025 | October 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date January 20, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right ot Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2033-01-20 | Direct | 25,400 |
Reported balance
After 2023-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 25,400 · Balance 25,400 F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Aquestive Therapeutics, Inc.
Report date October 15, 2025 · Filed October 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 282,475 |
Reported balance
After 2025-10-15 transaction · row 1
1 source rowRow 1 · 2025-10-15 · Sale · Disposed 20,272 · Balance 282,475 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. F2: The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
F2: The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2025 Filed Oct 17, 2025 18:01 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 20,272 | $7.00 | $141,904.00 |
DisclosureSEC source: 0001214659-25-015047 · marketforms-71050.xml · nonDerivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,475 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. F2 · price: The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2025 Filed Aug 12, 2025 14:11 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 10,819 | $3.90 | $42,194.10 |
DisclosureSEC source: 0001214659-25-011823 · marketforms-70221.xml · nonDerivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,747 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-25-004225 · marketforms-68573.xml · derivative · entry 3 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 8,115 | $2.65 | $21,504.75 |
DisclosureSEC source: 0001214659-25-004225 · marketforms-68573.xml · nonDerivative · entry 2 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,566 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-004225 · marketforms-68573.xml · nonDerivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,681 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 18:45 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 10,819 | $3.43 | $37,109.17 |
DisclosureSEC source: 0001214659-24-014226 · marketforms-66654.xml · nonDerivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,681 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001214659-24-004306 · marketforms-64692.xml · derivative · entry 2 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2034-03-07 F2 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004306 · marketforms-64692.xml · nonDerivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,500 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-010919 · marketforms-62126.xml · nonDerivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment Read SEC document |
| January 20, 2023 Filed Feb 2, 2023 20:10 UTC | Aceragen, Inc. ACGN · Entity 110652 | GrantStock Options (Right ot Buy) · Derivative | 25,400 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001415889-23-001856 · form4-02032023_010245.xml · derivative · entry 1 Kraus Carl N · CIK 0001946475 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Underlying: Common Stock · 25,400 shares Expires 2033-01-20 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:46 UTC | Aceragen, Inc. ACGN · Entity 110652 | Exercise / conversionOptions (Right to Buy) · Derivative | 440,844 | Not disclosed Strike: $208.76 | Not disclosed |
DisclosureSEC source: 0001104659-23-005134 · tm233989-2_4seq1.xml · derivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,844 Underlying: Common Stock · 440,844 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · price: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F2 · derivative.exercise_date: The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. F3 · derivative.underlying_shares: Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 21:48 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantSeries Z Preferred Stock · Derivative | 6,843 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-104795 · tm2227191-7_4seq1.xml · derivative · entry 3 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,843 Underlying: Common Stock · 6,843,000 shares Expires not disclosed F4 · derivative.exercise_price: Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations (represents Series Z Preferred Stock options issuable upon the exercise of the Series Z Stock options reported above). F1 · kind: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022 (the "Merger Agreement"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Shares of Aceragen common stock convertible into shares of common stock of Idera, par value $0.001 per share ("Common Stock") and shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F1 · price: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022 (the "Merger Agreement"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Shares of Aceragen common stock convertible into shares of common stock of Idera, par value $0.001 per share ("Common Stock") and shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F4 · derivative.exercise_date: Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations (represents Series Z Preferred Stock options issuable upon the exercise of the Series Z Stock options reported above). F4 · derivative.expiration_date: Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations (represents Series Z Preferred Stock options issuable upon the exercise of the Series Z Stock options reported above). Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 21:48 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantOptions (Right to Buy) · Derivative | 6,843 | Not disclosed Strike: $12,280.00 | Not disclosed |
DisclosureSEC source: 0001104659-22-104795 · tm2227191-7_4seq1.xml · derivative · entry 2 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,843 Underlying: Series Z Preferred Stock · 6,843 shares Expires 2032-02-09 F1 · kind: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022 (the "Merger Agreement"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Shares of Aceragen common stock convertible into shares of common stock of Idera, par value $0.001 per share ("Common Stock") and shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F3 · price: Pursuant to the Merger Agreement, the Reporting Person received Idera options for 651,364 shares of Common Stock and options for 6,843 shares of Series Z Preferred Stock options in exchange for 300,000 Aceragen options. F2 · derivative.exercise_date: The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 21:48 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantOptions (Right to Buy) · Derivative | 651,364 | Not disclosed Strike: $12.28 | Not disclosed |
DisclosureSEC source: 0001104659-22-104795 · tm2227191-7_4seq1.xml · derivative · entry 1 Kraus Carl N · CIK 0001946475 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,364 Underlying: Common Stock · 651,364 shares Expires 2032-02-09 F1 · kind: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022 (the "Merger Agreement"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Shares of Aceragen common stock convertible into shares of common stock of Idera, par value $0.001 per share ("Common Stock") and shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F3 · price: Pursuant to the Merger Agreement, the Reporting Person received Idera options for 651,364 shares of Common Stock and options for 6,843 shares of Series Z Preferred Stock options in exchange for 300,000 Aceragen options. F2 · derivative.exercise_date: The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.